Coadminitration with rifampin decreases AUC and peak by 32 and 21%, respectively
Increases warfarin INR
Weak, reversible, nonselective MAO inhibitor, leading to a risk of serotonin syndrome if coadministered with other MAOIs (and may SSRIs)
References
^Zhiyi Lan, Nafees Ahmad, Parvaneh Baghaei, Linda Barkane, Andrea Benedetti, Sarah K Brode, James C M Brust, Jonathon R Campbell, Vicky Wai Lai Chang, Dennis Falzon, Lorenzo Guglielmetti, Petros Isaakidis, Russell R Kempker, Maia Kipiani, Liga Kuksa, Christoph Lange, Rafael Laniado-Laborín, Payam Nahid, Denise Rodrigues, Rupak Singla, Zarir F Udwadia, Dick Menzies, N Ahmad, P Baghaei, L Barkane, A Benedetti, SK Brode, JCM Brust, JR Campbell, VWL Chang, D Falzon, L Guglielmetti, P Isaakidis, RR Kempker, M Kipiani, L Kuksa, Z Lan, C Lange, R Laniado-Laborín, P Nahid, D Rodrigues, R Singla, ZF Udwadia, D Menzies. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet Respiratory Medicine. 2020;8(4):383-394. doi:10.1016/s2213-2600(20)30047-3.
^G. B. Migliori, B. Eker, M. D. Richardson, G. Sotgiu, J-P. Zellweger, A. Skrahina, J. Ortmann, E. Girardi, H. Hoffmann, G. Besozzi, N. Bevilacqua, D. Kirsten, R. Centis, C. Lange. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. European Respiratory Journal. 2009;34(2):387-393. doi:10.1183/09031936.00009509.